Guanabenz acetate

PreclinicalSmall molecule

KKathy Miller

Guanabenz acetate is one of 22 small molecule programs targeting Bone Metastasis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bone MetastasisActive, not recruiting

Bone MetastasisPreclinical

Active, not recruiting

Competition

Competitive Landscape

24 competitors in Bone Metastasis

#DrugCompanyPhaseTrials

Zometa

Pfizer

Approved

12 2

Duragesic

Tanezumab

1 4

Comparator: Pbo

Merck & Co.

Phase 3

1 5

Nolvadex

AstraZeneca

Phase 2

1 6

Aromasin

Pfizer

Phase 2

1 7

Ibrance

Pfizer

Phase 2

1 8

Femara

Novartis

Phase 2

1 9

Xtandi

Astellas

Phase 2

1 10

Odanacatib

Merck & Co.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bone Metastasis1 trial

Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis

Terminated·KKathy Miller·N/A·NCT02443103·4 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Guanabenz acetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Guanabenz acetate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Guanabenz acetate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kathy Miller company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: KKathy Miller

Guanabenz acetate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bone Metastasis1 trial

References

Drug Info

Quick Facts

Related News